Axios Science on MSN29d
Mass. files suit accusing insulin makers of price-gougingMassachusetts is the latest state going after insulin makers and the intermediaries officials accuse of price gouging. Why it matters: Diabetes patients are often paying hundreds of dollars a month or ...
The Associated Press on MSN29d
Newsom Committed California to Making Its Own Insulin. It’s at Least a Year Behind His ScheduleGov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind schedule ...
Despite being off-patent for many years, Humalog and other insulin brands continue to make high sales, with Lilly booking around $3 billion from its product last year, $1.8 billion of which was ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
As insulin prices in the United States continue to rise, making it increasingly difficult for diabetic patients to afford ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two ...
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback